Katoh, N.

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J. ‐., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., et al. (2021) · British Journal of Dermatology

Dermatology and Skin DiseasesAsthma and respiratory diseases

Cited by 638

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Guttman-Yassky, E., Teixeira, H. D., Simpson, E. L., Papp, K. A., Pangan, A. L., Blauvelt, A., Thaçi, D., Chu, C.-Y., Hong, H. C.-H., Katoh, N., et al. (2021) · The Lancet

Dermatology and Skin DiseasesAsthma and respiratory diseases

Cited by 583

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

Bieber, T., Thyssen, J. P., Reich, K., Simpson, E. L., Katoh, N., Torrelo, A., De Bruin‐Weller, M., Thaci, D., Bissonnette, R., Gooderham, M., et al. (2021) · Journal of the European Academy of Dermatology and Venereology

Dermatology and Skin DiseasesDrug-Induced Adverse Reactions

Cited by 152

The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells

Wada, M., Horinaka, M., Yamazaki, T., Katoh, N., & Sakai, T. (2014) · PLoS ONE

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 50

Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*

Thomas, K. S., Apfelbacher, C. A., Chalmers, J. R., Simpson, E., Spuls, P. I., Gerbens, L. A. A., Williams, H. C., Schmitt, J., Gabes, M., Howells, L., et al. (2021) · British Journal of Dermatology

Dermatology and Skin DiseasesDelphi Technique in Research

Cited by 13